A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Launched by CONTEXT THERAPEUTICS INC. · Jul 19, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called CTIM-76 for patients with certain types of cancer, including recurring ovarian cancer that is resistant to platinum-based therapies, as well as advanced testicular and endometrial cancers. The main goal of the study is to find out if this new drug is safe and effective for people whose cancers have not responded to other treatments. The study is currently recruiting participants aged 65 and older who have specific types of cancer that show certain characteristics, such as being positive for a protein called CLDN6.

If you or a loved one is considering joining this trial, you should know that participants will be carefully monitored for their health and any side effects while receiving CTIM-76. To be eligible, participants should have measurable cancer that hasn’t been effectively treated before, and their overall health must be stable enough to handle the study procedures. However, individuals with certain conditions, such as active infections or prior treatment targeting CLDN6, will not qualify. This trial aims to offer hope for patients with limited treatment options, and it could contribute to finding new ways to fight these challenging cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects with CLDN6 positive platinum resistant/refractory ovarian, advanced testicular or advanced endometrial cancer.
• • Subject with measurable disease per RECIST 1.1
• • ECOG 0, 1, or 2
• • Subjects with adequate organ function.
• Exclusion Criteria:
• • Evidence of central nervous system metastases, leptomeningeal disease or spinal cord compression.
• • Uncontrolled significant active infection or any medical or other condition that in opinion of the investigator would preclude the subject's participation in the study.
• • Prior treatment with CLDN-6 targeted therapy.
• • Concurrent participation in another investigational clinical trial.